Selecta Biosciences
Pioneering RNA cell therapy for autoimmune disease.
Launch date
Employees
Market cap
€326m
Enterprise valuation
€131m (Public information from Sep 2024)
Share price
$16.03 SELB
Watertown Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 16.6m | 85.1m | 111m | 26.0m | 44.5m | 13.4m | 17.7m |
% growth | 149 % | 413 % | 30 % | (77 %) | 71 % | (70 %) | 32 % |
EBITDA | (56.7m) | (4.6m) | 16.2m | - | - | - | - |
% EBITDA margin | (342 %) | (5 %) | 15 % | - | - | - | - |
Profit | (68.9m) | (25.7m) | 35.4m | (220m) | (75.8m) | (79.3m) | (101m) |
% profit margin | (415 %) | (30 %) | 32 % | (845 %) | (171 %) | (592 %) | (570 %) |
EV / revenue | 19.7x | 4.5x | 1.6x | 4.1x | 1.9x | -0.6x | 7.3x |
EV / EBITDA | -5.8x | -82.9x | 10.7x | - | - | - | - |
R&D budget | 54.5m | 68.7m | 72.4m | - | - | - | - |
R&D % of revenue | 328 % | 81 % | 65 % | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.5m | Seed | ||
$15.1m | Series B | ||
$15.0m | Series C | ||
$47.3m | Series D | ||
$22.0m | Series D | ||
N/A | $5.3m | Early VC | |
N/A | $4.5m | Debt | |
N/A | $3.2m | Grant | |
N/A | $5.9m | Early VC | |
$38.0m | Series E | ||
N/A | N/A | IPO | |
N/A | $5.0m | Post IPO Equity | |
$21.0m | Debt | ||
N/A | $5.8m | Post IPO Equity | |
N/A | $35.0m | Post IPO Debt | |
* | N/A | $38.7m | Post IPO Equity |
* | N/A | $60.3m | Private Placement VC |
* | N/A | Acquisition | |
Total Funding | €195m |
Recent News about Selecta Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.